We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Surrogate Endpoint for ARYx Anticoagulant
FDA Approves Surrogate Endpoint for ARYx Anticoagulant
January 8, 2010
An additional trial in a real world setting comparing ARYx Therapeutics’ novel anticoagulant agent, tecarfarin, with warfarin, the leading anticoagulant,
could be enough to establish tecarfarin’s superiority, ARYx says.